STEM-META: Targeting Muscle Performance
Immunis is planning a Phase 2 placebo-controlled clinical trial to continue safety and efficacy assessments of IMM01-STEM on addressing muscle performance in seniors with obesity and muscle weakness.
IMM01-STEM Benefits Muscle Function and Metabolism (Preclinical Data)
Immunis Scientific Advisory Board member, Professor Micah Drummond, published preclinical research in Aging Cell supporting that Immunis’ investigational secretome enhances muscle mass and strength in aged mouse models, while increasing metabolism and reducing fat.
Aged mice received intramuscular injections of IMM01-STEM twice a week, for four consecutive week, totaling 8 injections. Compared to control-treated, aged mice, IMM01-STEM increases whole-body lean mass and reduces fat mass, while increasing muscle size, enhancing muscle regeneration, and improving muscle function. These preclinical data demonstrate that Immunis’ novel therapy increases metabolism without compromising muscle mass.
The U.S. Food and Drug Administration granted Immunis permission to conduct a Phase 2 clinical trial investigating IMM01-STEM on muscle function in patients with sarcopenic obesity (age-related muscle loss and obesity).
Read the publication below or check out the video below for the results from our Aging Cell publication.
Stem cell secretome treatment improves whole-body metabolism, reduces adiposity, and promotes skeletal muscle function in aged mice
Fennel, Zachary J., Paul-Emile Bourrant, Anu Susan Kurian, Jonathan J. Petrocelli, Naomi M. M. P. de Hart, Elena M. Yee, Sihem Boudina, et al. “Stem Cell Secretome Treatment Improves Whole-Body Metabolism, Reduces Adiposity, and Promotes Skeletal Muscle Function in Aged Mice.” Aging Cell. (March 3, 2024): e14144. https://doi.org/10.1111/acel.14144.